Medical Cannabis for Bipolar Disorder — Switzerland 2026
In bipolar disorder THC is critical (mania risk), but CBD may work as an add-on mood stabilizer. Close psychiatric monitoring mandatory.
TL;DR: ~150,000 people in Switzerland live with bipolar disorder. THC is contraindicated in Bipolar I (mania risk!). CBD however shows antimanic and anxiolytic effects in Zulkifly 2020 and small 2022–2024 studies — pure add-on to lithium/valproate/quetiapine, under psychiatric control. Members: 50 CHF instead of 190.
What the studies show
Zulkifly 2020: CBD inhibits manic symptoms in the amphetamine model — preclinically convincing.
Pinto 2020 (J Psychopharmacol, small RCT): CBD add-on in bipolar depression significantly improves HAMD score.
WARNING: THC can trigger mania and psychosis in predisposed individuals — strictly avoid in Bipolar I.
Preparations & dosing
PURE CBD isolate or broad spectrum (THC <0.05 %): 100–300 mg/day, split into 2 doses.
Standard therapy (lithium, valproate, quetiapine, lamotrigine) MUST be continued — CBD is add-on.
Close psychiatric monitoring first 3 months. Manic prodromes: immediate discontinuation.
Save as a CannabisClub member
Psychiatric cannabis consultation: 220–300 CHF. Members: 50 CHF flat (pure CBD prescriptions only). Registration free.
FAQ
Can I take THC?
No. Strictly contraindicated in Bipolar I — mania risk. Only pure CBD under psychiatric control.
What does membership save?
50 CHF instead of 190 CHF per consultation. Registration free.
Does insurance cover it?
No — CBD in bipolar is not a standard indication. Out of pocket.